SeaStar Medical's Q4 revenue rises, net loss narrows

SeaStar Medical Holding

25/03/2026 20:32

Overview

U.S. organ failure therapy maker's Q4 revenue rose sharply yr/yr, driven by expanded hospital sales

Net loss for Q4 narrowed compared to prior year due to reduced operating expenses

Company completed key clinical trial milestones and improved balance sheet with increased capital

Outlook

SeaStar Medical anticipates about $2 mln in net product revenue in 2026

Company aims to add 15 top-ranked children’s medical centers for QUELIMMUNE in 2026

SeaStar Medical expects to complete NEUTRALIZE-AKI pivotal trial enrollment by end-2026

Result Drivers

HOSPITAL ADOPTION - Revenue growth driven by expanded sales of QUELIMMUNE therapy to additional top-rated children's hospitals

CLINICAL TRIAL PROGRESS - Achieved over 50% enrollment in pivotal adult AKI trial and completed SAVE Registry enrollment, supporting future growth initiatives

OPERATING COST REDUCTION - Lower research and development and general administrative expenses contributed to a narrower net loss

Company press release: ID:nGNX6ddN2K

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$420,000
Q4 EPS
-$0.80
Q4 Net Income
-$2.90 mln
Q4 Operating Expenses
$3.42 mln
Q4 Operating Income
-$3.02 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for SeaStar Medical Holding Corp is $9.00, about 301.8% above its March 24 closing price of $2.24

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)